Skip to main content

Advertisement

Table 2 Comparison of the pro-inflammatory cytokine profile before and after 12 weeks treatment with metformin or rimonabant

From: Endocannabinoid receptor blockade reduces alanine aminotransferase in polycystic ovary syndrome independent of weight loss

Parameter Metformin group (n = 10) Rimonabant group (n = 10)
Baseline 12 weeks P-value Baseline 12 weeks P-value
IL-1β 86 ± 56 105 ± 89 0.17 85 ± 77 91 ± 91 0.32
IL-6 12 ± 6 13 ± 7 0.31 17 ± 8 18 ± 9 0.31
IL-7 249 ± 18 252 ± 31 0.69 235 ± 47 263 ± 49 0.11
IL-10 23 ± 32 27 ± 30 0.29 10 ± 6 10 ± 6 0.92
IL-12 203 ± 60 223 ± 83 0.11 201 ± 41 207 ± 33 0.50
TNF-α ± 3 ± 4 0.33 ± 4 ± 4 0.99
MCP-1 294 ± 66 298 ± 88 0.80 279 ± 60 307 ± 58 0.6
INF-γ 30 ± 10 30 ± 9 0.83 30 ± 7 36 ± 9 0.6
  1. No difference in the inflammatory cytokine profile between metformin and rimonabant treated patients
  2. IL interleukin, TNF tumour necrosis factor, MCP monocyte chemotactic protein, INF interferon